Recurrent research hub

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic, or Persistent Cervical Carcinoma

This study is testing an immunotherapy called LN-145 for women with cervical cancer that has come back, spread, or hasn't responded to other treatments. It's looking at how well the treatment shrinks tumours and if it's safe to use.